Amends existing law to revise provisions regarding controlled substances.

LEGISLATURE OF THE STATE OF IDAHO Sixty-eighth Legislature Second Regular Session - 2026 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. 497 BY HEALTH AND WELFARE COMMITTEE AN ACT1 RELATING TO UNIFORM CONTROLLED SUBSTANCES; AMENDING SECTION 37-2705, IDAHO2 CODE, TO REVISE PROVISIONS REGARDING SCHEDULE I CONTROLLED SUBSTANCES3 AND TO MAKE TECHNICAL CORRECTIONS; AMENDING SECTION 37-2707, IDAHO4 CODE, TO REVISE PROVISIONS REGARDING SCHEDULE II CONTROLLED SUBSTANCES5 AND TO MAKE TECHNICAL CORRECTIONS; AMENDING SECTION 37-2709, IDAHO6 CODE, TO REVISE PROVISIONS REGARDING SCHEDULE III CONTROLLED SUB-7 STANCES AND TO MAKE TECHNICAL CORRECTIONS; AMENDING SECTION 37-2711,8 IDAHO CODE, TO REVISE PROVISIONS REGARDING SCHEDULE IV CONTROLLED SUB-9 STANCES AND TO MAKE TECHNICAL CORRECTIONS; AMENDING SECTION 37-2713,10 IDAHO CODE, TO REVISE PROVISIONS REGARDING SCHEDULE V CONTROLLED SUB-11 STANCES; AMENDING SECTION 37-2716, IDAHO CODE, TO REVISE PROVISIONS12 REGARDING REGISTRATION REQUIREMENTS; AMENDING SECTION 37-2717, IDAHO13 CODE, TO REVISE A PROVISION REGARDING REGISTRATION; AMENDING SEC-14 TION 37-2718, IDAHO CODE, TO REVISE PROVISIONS REGARDING DISCIPLINE;15 AMENDING SECTION 37-2719, IDAHO CODE, TO REVISE PROVISIONS REGARD-16 ING ORDERS TO SHOW CAUSE; AMENDING SECTION 37-2720, IDAHO CODE, TO17 REVISE A PROVISION REGARDING RECORDS, DRUG STORAGE, AND INVENTORY;18 AMENDING SECTION 37-2722, IDAHO CODE, TO REVISE PROVISIONS REGARDING19 ISSUING, DISTRIBUTING, AND DISPENSING OF CONTROLLED SUBSTANCES AND TO20 MAKE TECHNICAL CORRECTIONS; AMENDING SECTION 37-2726, IDAHO CODE, TO21 REVISE PROVISIONS REGARDING THE CONTROLLED SUBSTANCES PRESCRIPTIONS22 DATABASE; AMENDING SECTION 37-2731, IDAHO CODE, TO REVISE A PROVISION23 REGARDING INFORMATION REQUIRED ON LABELS; AND DECLARING AN EMERGENCY24 AND PROVIDING AN EFFECTIVE DATE.25

Be It Enacted by the Legislature of the State of Idaho:26

SECTION 1. That Section 37-2705, Idaho Code, be, and the same is hereby27 amended to read as follows:28 37-2705. SCHEDULE I. (a) The controlled substances listed in this sec-29 tion are included in schedule I.30 (b) Any of the following opiates, including their isomers, esters,31 ethers, salts, and salts of isomers, esters, and ethers, unless specifically32 excepted, whenever the existence of these isomers, esters, ethers and salts33 is possible within the specific chemical designation:34 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-pip-35 eridinyl]-N-phenylacetamide);36 (2) Acetylmethadol;37 (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylac-38 etamide);39 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacry-40 lamide);41 (5) Allylprodine;42

2 (6) Alphacetylmethadol (except levo-alphacetylmethadol also known as1 levo-alpha-acetylmethadol, levomethadyl acetate or LAAM);2 (7) Alphameprodine;3 (8) Alphamethadol;4 (9) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidi-5 n-4-yl)-N-phenylbutanamide);6 (10) Alpha-methylfentanyl;7 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-8 piperidinyl]-N-phenylpropanamide);9 (12) Benzethidine;10 (13) Betacetylmethadol;11 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperid-12 inyl]-N-phenylpropanamide);13 (15) Beta-hydroxythiofentanyl;14 (16) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-phenethyl)-3-15 methyl-4-piperidinyl)-N-phenylpropanamide);16 (17) Betameprodine;17 (18) Betamethadol;18 (19) Beta-methyl fentanyl;19 (20) Beta-methylacetyl fentanyl;20 (20) (21) Beta'-phenyl fentanyl;21 (21) (22) Betaprodine;22 (22) (23) Brorphine (1-(1-(1-(4-Bromophenyl)ethyl)piperidin-4-yl)-23 1,3-dihydro-2H-benzo[D]imidazol-2-one);24 (23) (24) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1hbenzimida-25 zol-1-yl)-N,N-diethylethan-1-amine);26 (24) (25) Clonitazene;27 (25) (26) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-28 phenylbut-2-enamide);29 (26) (27) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-30 phenylcyclopentanecarboxamide);31 (27) (28) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-32 phenylcyclopropanecarboxamide);33 (28) (29) Dextromoramide;34 (29) (30) Diampromide;35 (30) (31) Diethylthiambutene;36 (31) (32) Difenoxin;37 (32) (33) Dimenoxadol;38 (33) (34) Dimepheptanol;39 (34) (35) 2',5'-Dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)pip-40 eridin-4-yl)-N-phenylpropionamide);41 (35) (36) Dimethylthiambutene;42 (36) (37) Dioxaphetyl butyrate;43 (37) (38) Dipipanone;44 (38) (39) Ethylmethylthiambutene;45 (39) (40) Etodesnitazene; (Etazene) (2-(2-(4-ethoxybenzyl)-1hbenzim-46 idazol-1-yl)-N,N-diethylethan-1-amine);47 (40) (41) Etonitazene;48 (41) (42) Etoxeridine;49

3 (42) (43) Fentanyl-related substances. "Fentanyl-related substances"1 means any substance not otherwise listed and for which no exemption or2 approval is in effect under section 505 of the federal food, drug, and3 cosmetic act, 21 U.S.C. 355, and that is structurally related to fen-4 tanyl by one (1) or more of the following modifications:5 i. Replacement of the phenyl portion of the phenethyl group by any6 monocycle, whether or not further substituted in or on the monocy-7 cle;8 ii. Substitution in or on the phenethyl group with alkyl, alkenyl,9 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;10 iii. Substitution in or on the piperidine ring with alkyl,11 alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino,12 or nitro groups;13 iv. Replacement Substitution in or on the aniline ring or replace-14 ment of the aniline ring with any aromatic monocycle, whether or15 not further substituted in or on the aromatic monocycle; and/or16 v. Replacement of the N-propionyl group by another acyl group;17 (43) (44) Fentanyl carabamate;18 (44) (45) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1h-19 benzimidazol-1-yl)ethan-1-amine);20 (45) (46) 4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-21 phenethylpiperidin-4-yl)isobutyramide);22 (46) (47) 2'-fluoro ortho-fluorofentanyl;23 (47) (48) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyl-24 furan-2-carboxamide);25 (48) (49) 3-Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-26 phenylfuran-3-carboxamide);27 (49) (50) Furethidine;28 (50) (51) Hydroxypethidine;29 (51) (52) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-30 phenylisobutyramide);31 (52) (53) Isovalery fentanyl (3-methyl-N-(1-phenethylpiperidin-4-32 yl)-N-phenylbutanimide);33 (53) (54) Isotonitazene (N,N-diethyl-2-(2-(4isopropoxybenzyl)-5-ni-34 tro-1h-benzimidazol-1-yl)ethan-1-amine);35 (54) (55) Ketobemidone;36 (55) (56) Levomoramide;37 (56) (57) Levophenacylmorphan;38 (57) (58) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-39 phenethylpiperidin-4-yl)isobutyramide);40 (59) Meta-fluorofuranyl fentanyl;41 (58) (60) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-42 phenethylpiperidin-4-yl)isobutyramide);43 (59) (61) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-44 4-yl)-N-phenylacetamide);45 (60) (62) 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-46 yl)piperazin-1-yl)butan-1-one);47 (61) (63) 4'-methyl acetyl fentanyl;48 (62) (64) 3-Methylfentanyl;49

4 (63) (65) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-1 piperidinyl]-N-phenylpropanamide) (and optical and geometric isomers2 of 3-methylthiofentanyl);3 (64) (66) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1h-4 benzimidazol-1-yl)ethan-1-amine);5 (65) (67) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-ni-6 tro-1hbenzimidazol-1-yl)ethan-1-amine);7 (66) (68) Morpheridine;8 (67) (69) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);9 (68) (70) MT-45 (1-cyclohexyl-4- (1,2-diphenylethyl)piperazine);10 (69) (71) N-(4-chlorophenyl)-N-(1-phenethylpiperdin-4-yl)Isobutyra-11 mide (pPara-chloroisobutyrl fentanyl);12 (70) (72) Noracymethadol;13 (71) (73) Norlevorphanol;14 (72) (74) Normethadone;15 (73) (75) Norpipanone;16 (76) N-desethyl isotonitazene;17 (77) N-piperidinyl etonitazene;18 (74) (78) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-ni-19 tro-1-(2-(pyrrolidin-1-yl)ethyl)1hbenzimidazole);20 (75) (79) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethyl-21 piperidin-4-yl)acetamide);22 (80) Ortho-chlorofentanyl;23 (76) (81) Ortho-fluoroacryl fentanyl;24 (77) (82) Ortho-fluorobutyrl fentanyl;25 (78) (83) Ortho-fluorofentanyl;26 (79) (84) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-27 phenethylpiperidin-4-yl)furan-2-carboxamide);28 (80) (85) Ortho-fluoroisobutyryl fentanyl;29 (81) (86) Ortho-methyl acetylfentanyl;30 (87) Ortho-methylcyclopropylfentanyl;31 (82) (88) Ortho-methyl methoxyacetyl fentanyl;32 (89) Para-chlorofentanyl;33 (83) (90) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-34 phenethylpiperidin-4-yl) isobutyramide);35 (84) (91) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-36 phenethylpiperidin-4-yl) butyramide);37 (85) (92) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phen-38 ethyl)-4-piperidinyl] propanamide);39 (86) (93) Para-fluoro furanyl fentanyl;40 (94) Para-fluoro valeryl fentanyl;41 (87) (95) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-42 phenethylpiperidin-4-yl) butyramide);43 (88) (96) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-44 phenethylpiperidin-4-yl)furan-2-carboxamide);45 (89) (97) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-46 phenylpiperidin-4-yl)cyclopropanecarboxamide);47 (90) (98) Para-methylfentanyl;48 (91) (99) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);49 (92) (100) Phenadoxone;50

5 (93) (101) Phenampromide;1 (94) (102) Phenomorphan;2 (95) (103) Phenoperidine;3 (96) (104) Phenyl fentanyl;4 (97) (105) Piritramide;5 (98) (106) Proheptazine;6 (99) (107) Properidine;7 (100) (108) Propiram;8 (101) (109) Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxyben-9 zyl)-1h-benzimidazol-1-yl)ethan-1-amine);10 (102) (110) Racemoramide;11 (103) (111) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperi-12 dine-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);13 (112) Tetrahydrothiofuranyl fentanyl;14 (104) (113) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piper-15 idinyl]-propanamide);16 (105) (114) Tilidine;17 (106) (115) Trimeperidine;18 (107) (116) u-47700 (3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-19 methylbenzamide);20 (108) (117) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-21 phenylpentanamide);22 (109) (118) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piper-23 azin-1-yl]-1-phenylpropan-2-ol).24 (c) Any of the following opium derivatives, their salts, isomers and25 salts of isomers, unless specifically excepted, whenever the existence of26 these salts, isomers and salts of isomers is possible within the specific27 chemical designation:28 (1) Acetorphine;29 (2) Acetyldihydrocodeine;30 (3) Benzylmorphine;31 (4) Codeine methylbromide;32 (5) Codeine-N-Oxide;33 (6) Cyprenorphine;34 (7) Desomorphine;35 (8) Dihydromorphine;36 (9) Drotebanol;37 (10) Etorphine (except hydrochloride salt);38 (11) Heroin;39 (12) Hydromorphinol;40 (13) Methyldesorphine;41 (14) Methyldihydromorphine;42 (15) Morphine methylbromide;43 (16) Morphine methylsulfonate;44 (17) Morphine-N-Oxide;45 (18) Myrophine;46 (19) Nicocodeine;47 (20) Nicomorphine;48 (21) Normorphine;49 (22) Pholcodine;50

6 (23) Thebacon.1 (d) Hallucinogenic substances. Any material, compound, mixture or2 preparation that contains any quantity of the following hallucinogenic3 substances, their salts, isomers and salts of isomers, unless specifically4 excepted, whenever the existence of these salts, isomers, and salts of iso-5 mers is possible within the specific chemical designation (for purposes of6 this subsection only, the term "isomer" includes the optical, position and7 geometric isomers):8 (1) Dimethoxyphenethylamine, or any compound not specifically9 excepted or listed in another schedule that can be formed from10 dimethoxyphenethylamine by replacement of one (1) or more hydrogen11 atoms with another atom(s), functional group(s) or substructure(s)12 including, but not limited to, compounds such as DOB, DOC, 2C-B,13 25B-NBOMe;14 (2) Methoxyamphetamine or any compound not specifically excepted or15 listed in another schedule that can be formed from methoxyamphetamine16 by replacement of one (1) or more hydrogen atoms with another atom(s),17 functional group(s) or substructure(s) including, but not limited to,18 compounds such as PMA and DOM;19 (3) 5-methoxy-3,4-methylenedioxy-amphetamine;20 (4) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);21 (5) Amphetamine or methamphetamine with a halogen substitution on the22 benzyl ring, including compounds such as fluorinated amphetamine and23 fluorinated methamphetamine;24 (6) 3,4-methylenedioxy amphetamine (MDA);25 (7) 3,4-methylenedioxymethamphetamine (MDMA);26 (8) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-et-27 hyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-et-28 hyl MDA, MDE, MDEA);29 (9) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hyd-30 roxy-alpha-methyl-3,4(methylenedioxy) phenethylamine, and N-hyd-31 roxy MDA);32 (10) 3,4,5-trimethoxy amphetamine;33 (11) 5-methoxy-N,N-dimethyltryptamine (also known as 5-methoxy-3-2[2-34 (dimethylamino)ethyl]indole and 5-MeO-DMT);35 (12) Alpha-ethyltryptamine (some other names: etryptamine, 3-(2-am-36 inobutyl) indole AET);37 (13) Alpha-methyltryptamine (AMT);38 (14) Bufotenine;39 (15) Diethyltryptamine (DET);40 (16) Dimethyltryptamine (DMT);41 (17) Ibogaine;42 (18) Lysergic acid diethylamide (LSD);43 (19) Marihuana (marijuana);44 (20) Mescaline;45 (21) Methoxetamine;46 (22) Parahexyl;47 (23) Peyote;48 (24) N-ethyl-3-piperidyl benzilate;49 (25) N-methyl-3-piperidyl benzilate;50

7 (26) Para-methoxymethamphetamine (PMMA), 1-(4-methoxyphenyl)-N-1 methylpropan-2-amine;2 (27) Psilocybin;3 (28) Psilocyn;4 (29) Tetrahydrocannabinols or synthetic equivalents of the substances5 contained in the plant, or in the resinous extractives of Cannabis, sp.6 and/or synthetic substances, derivatives, and their isomers with simi-7 lar chemical structure such as the following:8 i. Tetrahydrocannabinols, except for the permitted amount of9 tetrahydrocannabinol found in industrial hemp, or nabiximols in a10 drug product approved by the United States food and drug adminis-11 tration:12 a. ∆ 1 cis or trans tetrahydrocannabinol, and their opti-13 cal isomers, excluding dronabinol in sesame oil and encapsu-14 lated in either a soft gelatin capsule or in an oral solution15 in a drug product approved by the U.S. Food and Drug Adminis-16 tration.17 b. ∆ 6 cis or trans tetrahydrocannabinol, and their optical18 isomers.19 c. ∆ 3,4 cis or trans tetrahydrocannabinol, and its optical20 isomers. (Since nomenclature of these substances is not in-21 ternationally standardized, compounds of these structures,22 regardless of numerical designation of atomic positions are23 covered.)24 d. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methy-25 loctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-26 1-o1)], also known as 6aR-trans-3-(1,1-dimethylhep-27 tyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-28 dibenzo[b,d]pyran-9-methanol (HU-210) and its geometric29 isomers (HU211 or dexanabinol).30 ii. The following synthetic drugs:31 a. Any compound structurally derived from (1H-indole-3-32 yl)(cycloalkyl, cycloalkenyl, aryl)methanone, or (1H-in-33 dole-3-yl)(cycloalkyl, cycloalkenyl, aryl)methane, or34 (1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl), methyl35 or dimethyl butanoate, amino-methyl (or dimethyl)-1-oxobu-36 tan-2-yl) carboxamide by substitution at the nitrogen atoms37 of the indole ring or carboxamide to any extent, whether or38 not further substituted in or on the indole ring to any ex-39 tent, whether or not substituted to any extent in or on the40 cycloalkyl, cycloalkenyl, aryl ring(s) (substitution in the41 ring may include, but is not limited to, heteroatoms such as42 nitrogen, sulfur and oxygen).43 b. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluo-44 ropentyl)-1 H-indazole-3-carboxamide (5F-AB-PINACA).45 c. 1-(1.3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one46 (N-ethylpentylone, (ephylone).47 d. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-inda-48 zole-3-carboxamide (4-cn-cumyl-BUTINACA).49

8 e. 5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-1 one (Cumyl PeGACLONE Pegaclone).2 f. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3carboxam-3 ido)-3,3-dimethylbutanoate * (5F-EDMB-PINACA).4 g. Ethyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-5 3,3-dimethylbutanoate (5F-EDMB-PICA).6 h. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3tetram-7 ethylcyclopropyl)methanone (FUB-144).8 i. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-inda-9 zole-3-carboxamide (5f-cumyl-pinaca; SGT-25).10 j. (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-111 H-pyrrolo[2.3-B]pyridine-3-carboxamide(5fcumyl-P7AICA).12 k. FUB-AMB, MMB- FUBINACA (Methyl 2-(1-(4-fluoroben-13 zyl)-1H-indazole-3-carboxamido)-3-methylbutanoate.14 l. MMB-FUBICA (Methyl 2-(1-(4-Fluorobenzyl)-1H-Indole-3-15 carboxamido)-3-methyl butanoate).16 m. Methyl 3,3-dimethyl-2-((1-(pent-4-en-1-yl)-1H-in-17 dazole-3-yl)formamidocarboxamido)butanoate (MDMB-4EN-18 PINACA).19 n. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-20 ido)-3-methylbutanoate (MMB-CHMICA, AMB-CHMICA).21 o. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-22 ido)-3,3-dimethylbutanoate (MDMB-CHMICA, MMB-CHMINACA).23 p. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxam-24 ido-3,3-dimethylbutanoate (MDMB-FUBINACA).25 q. Methyl 2-[[1-(4-Fluorobutyl)Indole-3-Carbonyl]Amino]-26 3,3-Dimethyl-Butanoate (4F-MDMB-BUTICA, 4F-MDMB-BICA).27 r. Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxam-28 ido)-3,3-dimethylbutanoate (5F-MDMB-PICA, 5F-MDMB-2201).29 s. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-30 ido)-3,3-dimethylbutanoate (5F-ADB, 5F-MDMB-PINACA).31 t. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-32 ido)-3-methylbutanoate (5F-AMB).33 u. N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-34 Indazole-3-carboxamide (ADB-BUTINACA).35 v. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluo-36 robenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA).37 w. N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-38 en-1-yl)-1H-indazole-3-carboxamide (ADB-4EN-PINACA).39 x. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-40 carboxamide (FUB-AKB48; FUB-APINACA).41 y. N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-42 carboxamide (5F-APINACA, 5F-AKB48).43 z. N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(Cyclohexyl-44 methyl)-1H-indazole-3-carboxamide (AB-CHMINACA).45 aa. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-car-46 boxylate (NM2201; CBL2201).47 bb. Any compound structurally derived from 3-(1-naph-48 thoyl)pyrrole by substitution at the nitrogen atom of the49 pyrrole ring to any extent, whether or not further sub-50

9 stituted in the pyrrole ring to any extent, whether or not1 substituted in the naphthyl ring to any extent.2 cc. Any compound structurally derived from 1-(1-naphthyl-3 methyl)indene by substitution at the 3-position of the in-4 dene ring to any extent, whether or not further substituted5 in the indene ring to any extent, whether or not substituted6 in the naphthyl ring to any extent.7 dd. Any compound structurally derived from 3-pheny-8 lacetylindole by substitution at the nitrogen atom of the9 indole ring to any extent, whether or not further substi-10 tuted in the indole ring to any extent, whether or not sub-11 stituted in the phenyl ring to any extent.12 ee. Any compound structurally derived from 2-(3-hydroxy-13 cyclohexyl)phenol by substitution at the 5-position of the14 phenolic ring to any extent, whether or not substituted in15 the cyclohexyl ring to any extent.16 ff. Any compound structurally derived from 3-(benzoyl)in-17 dole structure with substitution at the nitrogen atom of18 the indole ring to any extent, whether or not further sub-19 stituted in the indole ring to any extent and whether or not20 substituted in the phenyl ring to any extent.21 gg. [2,3-dihydro-5-methyl-3-(4-morpholinyl-22 methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-23 napthalenylmethanone (WIN-55,212-2).24 hh. 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (HU-25 243).26 ii. [(6S, 6aR, 9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-27 5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahy-28 drophenanthridin-1-yl]acetate (CP 50,5561).29 (30) Ethylamine analog of phencyclidine: N-ethyl-1-phenylcy-30 clohexylamine (1-phenylcyclohexyl) ethylamine; N-(1-phenylcy-31 clohexyl) ethylamine, cyclohexamine, PCE;32 (31) Pyrrolidine analog of phencyclidine: 1-(phenylcyclohexyl) -33 pyrrolidine, PCPy, PHP;34 (32) Thiophene analog of phencyclidine 1-[1-(2-thienyl)-cyclohexyl]-35 piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;36 (33) Thiofuranyl fentanyl;37 (34) (33) 1-[1-(2-thienyl) cyclohexyl] pyrrolidine another name:38 TCPy;39 (35) (34) Spores or mycelium capable of producing mushrooms that con-40 tain psilocybin or psilocin.41 (e) Unless specifically excepted or unless listed in another schedule,42 any material, compound, mixture or preparation which contains any quantity43 of the following substances having a depressant effect on the central ner-44 vous system, including its salts, isomers, and salts of isomers whenever the45 existence of such salts, isomers, and salts of isomers is possible within the46 specific chemical designation:47 (1) Bromazolam;48 (1) (2) Clonazolam;49 (2) (3) Diclazepam;50

10 (3) (4) Gamma hydroxybutyric acid (some other names include GHB; gam-1 ma-hydroxybutyrate, 4-hydroxybutyrate; 4-hyroxybutanoic acid; sod-2 ium oxybate; sodium oxybutyrate);3 (4) (5) Etizolam;4 (5) (6) Flualprazolam;5 (6) (7) Flubromazolam;6 (7) (8) Flunitrazepam (also known as R2, Rohypnol);7 (8) (9) Mecloqualone;8 (9) (10) Methaqualone.9 (f) Stimulants. Unless specifically excepted or unless listed in an-10 other schedule, any material, compound, mixture, or preparation which con-11 tains any quantity of the following substances having a stimulant effect on12 the central nervous system, including its salts, isomers, and salts of iso-13 mers:14 (1) Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-15 yl)amino]heptanoic acid);16 (2) Aminorex (some other names: (aminoxaphen), 2-amino-5-phenyl-2-17 oxazoline, or 4,5-dihydro-5-phenyl-2-oxazolamine), 4,4'-dimethylam-18 inorex (4,4'-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazo-19 lamine) or (4,5-dihydro-5-phenyl-2-oxazolamine);20 (3) Cathinone (some other names: 2-amino-1-phenol-1-propanone, alp-21 ha-aminopropiophenone, 2-aminopropiophenone and norephedrone);22 (4) Substituted cathinones. Any compound, except bupropion or com-23 pounds listed under a different schedule, structurally derived from24 2-aminopropan-1-one by substitution at the 1-position with either25 phenyl, naphthyl or thiophene ring systems, whether or not the compound26 is further modified in any of the following ways:27 i. By substitution in the ring system to any extent with alkyl,28 alkylenedioxy, alkoxy, haloalkyl, hydroxyl or halide sub-29 stituents, whether or not further substituted in the ring system30 by one (1) or more other univalent substituents;31 ii. By substitution at the 3-position with an acyclic alkyl sub-32 stituent;33 iii. By substitution at the 2-amino nitrogen atom with alkyl,34 dialkyl, benzyl or methoxybenzyl groups, or by inclusion of the35 2-amino nitrogen atom in a cyclic structure.36 (5) Alpha-pyrrolidinoheptaphenone* (PV8);37 (6) Alpha-pyrrolidinohexanophenone* (A-PHP);38 (7) 4-chloro-alpha-pyrrolidinovalerophenone* (4-chloro-a-pvp);39 (8) Ethylphenidate;40 (8) (9) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)bu-41 tan-1-one) (bk-EBDB);42 (9) (10) Fenethylline;43 (10) (11) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxa-44 diazol-3-ium-5-yl)carbamimidate);45 (11) (12) Methcathinone (some other names: 2-(methyl-amino)-pro-46 piophenone, alpha-(methylamino)-propiophenone, N-methylcathin-47 one, AL-464, AL-422, AL-463 and UR1423);48 (12) (13) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-49 amine);50

11 (13) (14) (+/-)cis-4-methylaminorex [(+/-)cis-4,5-dihydro-4-meth-1 yl-5-phenyl-2-oxazolamine];2 (14) (15) 4-methyl-alpha-ethylaminopentiophenone* (4-MEAP);3 (15) (16) 4'-methyl-alpha-pyrrolidinohexiophenone* (MPHP);4 (16) (17) 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-MMC);5 (17) (18) 4-methyl-1-phenyl-2-(pyrrolidine-1-yl)pent-1-one) (ALPHA-6 PIHP);7 (18) (19) N-benzylpiperazine (also known as: BZP, 1-benzylpiper-8 azine);9 (19) (20) N-ethylamphetamine;10 (20) (21) N-ethylhexedrone*;11 (21) (22) N,N-dimethylamphetamine (also known as: N,N-alpha-12 trimethyl-benzeneethanamine).13

SECTION 2. That Section 37-2707, Idaho Code, be, and the same is hereby14 amended to read as follows:15 37-2707. SCHEDULE II. (a) Schedule II shall consist of the drugs and16 other substances, by whatever official name, common or usual name, chemical17 name, or brand name designated, listed in this section.18 (b) Substances, vegetable origin or chemical synthesis. Unless19 specifically excepted or unless listed in another schedule, any of the fol-20 lowing substances whether produced directly or indirectly by extraction21 from substances of vegetable origin, or independently by means of chemical22 synthesis, or by a combination of extraction and chemical synthesis:23 (1) Opium and opiate, and any salt, compound, derivative, or prepa-24 ration of opium or opiate, excluding apomorphine, dextrorphan, nal-25 buphine, naldemedine, nalmefene, naloxegol, 6β-naltexol, naloxone,26 naltrexone, samidorphan, and their respective salts, but including the27 following:28 1. i. Raw opium;29 2. ii. Opium extracts;30 3. iii. Opium fluid extracts;31 4. iv. Powdered opium;32 5. v. Granulated opium;33 6. vi. Tincture of opium;34 7. vii. Codeine;35 8. viii. Dihydroetorphine;36 9. ix. Diprenorphine;37 10. x. Ethylmorphine;38 11. xi. Etorphine hydrochloride;39 12. xii. Hydrocodone;40 13. xiii. Hydromorphone;41 14. xiv. Metopon;42 15. xv. Morphine;43 xvi. Noroxymorphone;44 16. xvii. Oripavine;45 17. xviii. Oxycodone;46 18. xix. Oxymorphone;47 19. Tapentadol;48 20. xx. Thebaine.49

12 (2) Any salt, compound, derivative, or preparation thereof which is1 chemically equivalent or identical with any of the substances referred2 to in paragraph (1) of this subsection, except that these substances3 shall not include the isoquinoline alkaloids of opium.4 (3) Opium poppy and poppy straw.5 (4) Coca leaves and any salt, compound, derivative, or preparation6 of coca leaves, and any salt, compound, derivative, or preparation7 thereof which is chemically equivalent or identical with any of these8 substances, but shall not include the following:9 1. i. Decocainized coca leaves or extractions of coca leaves,10 which extractions do not contain cocaine; or ecgonine; or11 2. ii. [123I]ioflupane.12 (5) Benzoylecgonine.13 (6) Methylbenzoylecgonine (Cocaine, - its salts, optical and geometric14 isomers, and salts of optical and geometric isomers).15 (7) Concentrate of poppy straw (the crude extract of poppy straw in liq-16 uid, solid or powder form that contains the phenanthrine alkaloids of17 the opium poppy).18 (c) Any of the following opiates, including their isomers, esters,19 ethers, salts, and salts of isomers, whenever the existence of these iso-20 mers, esters, ethers and salts is possible within the specific chemical21 designation, unless specifically excepted or unless listed in another22 schedule:23 (1) Alfentanil;24 (2) Alphaprodine;25 (3) Anileridine;26 (4) Bezitramide;27 (5) Bulk Dextropropoxyphene (nondosage forms);28 (6) Carfentanil;29 (7) Dihydrocodeine;30 (8) Diphenoxylate;31 (9) Fentanyl;32 (10) Isomethadone;33 (11) Levo-alphacetylmethadol (also known as levo-alpha-acetylmet-34 hadol, levomethadyl acetate, LAAM);35 (12) Levomethorphan;36 (13) Levorphanol;37 (14) Metazocine;38 (15) Methadone;39 (16) Methadone -- Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl40 butane;41 (17) Moramide -- Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl42 propane-carboxylic acid;43 (18) Norfentanyl (N-phenyl-N-(piperidin-4-yl) propionamide);44 (19) (18) Oliceridine;45 (20) (19) Pethidine (meperidine);46 (21) (20) Pethidine -- Intermediate -- A, 4-cyano-1-methyl-4-phenyl-47 piperidine;48 (22) (21) Pethidine -- Intermediate -- B, ethyl-4-phenylpiperid-49 ine-4-carboxylate;50

13 (23) (22) Pethidine -- Intermediate -- C, 1-methyl-4-phenylpiperid-1 ine-4-carboxylic acid;2 (24) (23) Phenazocine;3 (25) (24) Piminodine;4 (26) (25) Racemethorphan;5 (27) (26) Racemorphan;6 (28) (27) Remifentanil;7 (29) (28) Sufentanil.;8 (29) Tapentadol;9 (30) Thiafentanil.10 (d) Stimulants. Unless specifically excepted or unless listed in an-11 other schedule, any material, compound, mixture, or preparation which con-12 tains any quantity of the following substances having a stimulant effect on13 the central nervous system:14 (1) Amphetamine, its salts, optical isomers, and salts of its optical15 isomers;16 (2) Lisdexamfetamine, its salts, isomers, and salts of its isomers;17 (3) Methamphetamine, its salts, isomers, and salts of its isomers;18 (4) Phenmetrazine and its salts;19 (5) Methylphenidate.20 (e) Depressants. Unless specifically excepted or unless listed in an-21 other schedule, any material, compound, mixture, or preparation which con-22 tains any quantity of the following substances having a depressant effect on23 the central nervous system, including its salts, isomers, and salts of iso-24 mers, whenever the existence of such salts, isomers, and salts of isomers is25 possible within the specific chemical designation:26 (1) Amobarbital;27 (2) Glutethimide;28 (3) Pentobarbital;29 (4) Phencyclidine;30 (5) Secobarbital.31 (f) Hallucinogenic substances.32 (1) Nabilone ............................ (another name for nabilone:33 (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hy-34 droxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one) (21 CFR 1308.12 (f)).35 (g) Immediate precursors. Unless specifically excepted or unless36 listed in another schedule, any material, compound, mixture, or preparation37 which contains any quantity of the following substances:38 (1) Immediate precursor to amphetamine and methamphetamine:39 (a) i. Anthranilic acid;40 (b) ii. Ephedrine;41 (c) iii. Lead acetate;42 (d) iv. Methylamine;43 (e) v. Methyl formamide;44 (f) vi. N-methylephedrine;45 (g) vii. Phenylacetic acid;46 (h) viii. Phenylacetone (phenyl-2-propanone, P2P);47 (i) ix. Phenylpropanolamine;48 (j) x. Pseudoephedrine.49

14 Except that any combination or compound containing ephedrine, or any of1 its salts and isomers, or phenylpropanolamine or its salts and isomers,2 or pseudoephedrine, or any of its salts and isomers which is prepared3 for dispensing or over-the-counter distribution is not a controlled4 substance for the purpose of this section, unless such substance is pos-5 sessed, delivered, or possessed with intent to deliver to another with6 the intent to manufacture methamphetamine, amphetamine or any other7 controlled substance in violation of section 37-2732, Idaho Code. For8 purposes of this provision, the requirements of the uniform controlled9 substances act shall not apply to a manufacturer, wholesaler or re-10 tailer of over-the-counter products containing the listed substances11 unless such person possesses, delivers, or possesses with intent to12 deliver to another the over-the-counter product with intent to manufac-13 ture a controlled substance.14 (2) Immediate precursors to phencyclidine (PCP):15 (a) i. 1-phenylcyclohexylamine;16 (b) ii. 1-piperidinocyclohexanecarbonitrile (PCC).17 (3) Immediate precursors to fentanyl:18 i. 4-anilino-N-phenethyl-4-piperidine (ANPP).;19 ii. Norfentanyl.20

SECTION 3. That Section 37-2709, Idaho Code, be, and the same is hereby21 amended to read as follows:22 37-2709. SCHEDULE III. (a) Schedule III shall consist of the drugs and23 other substances, by whatever official name, common or usual name, chemical24 name, or brand name designated, listed in this section.25 (b) Stimulants. Unless specifically excepted or unless listed in an-26 other schedule, any material, compound, mixture, or preparation which con-27 tains any quantity of the following substances having a stimulant effect on28 the central nervous system, including its salts, isomers, (whether optical,29 positional, or geometric), and salts of such isomers whenever the existence30 of such salts, isomers, and salts of isomers is possible within the specific31 chemical designation:32 (1) Those compounds, mixtures, or preparations in dosage unit form con-33 taining any stimulant substances listed in schedule II which compounds,34 mixtures, or preparations were listed as excepted compounds under 2135 CFR 1308.32, and any other drug of the quantitative composition shown in36 that list for those drugs or which is the same except that it contains a37 lesser quantity of controlled substances.38 (2) Benzphetamine;39 (3) Chlorphentermine;40 (4) Clortermine;41 (5) Phendimetrazine.42 (c) Depressants. Unless listed in another schedule, any material, com-43 pound, mixture, or preparation which contains any quantity of the following44 substances having a potential for abuse associated with a depressant effect45 on the central nervous system:46 (1) Any compound, mixture or preparation containing the following sub-47 stances or any salt thereof and one (1) or more other active medicinal48 ingredients that are not listed in any schedule:49

15 i. Amobarbital;1 ii. Secobarbital;2 iii. Pentobarbital or any salt thereof and one (1) or more other3 active medicinal ingredients which are not listed in any schedule.4 (2) Any suppository dosage form containing the following substances or5 any salt of any of these drugs and approved by the food and drug adminis-6 tration for marketing only as a suppository:7 i. Amobarbital;8 ii. Secobarbital;9 iii. Pentobarbital or any salt of any of these drugs and approved10 by the Food and Drug Administration for marketing only as a suppos-11 itory.12 (3) Any substance which contains any quantity of a derivative of barbi-13 turic acid or any salt thereof, including, but not limited to:14 i. Aprobarbital;15 ii. Butabarbital (secbutabarbital);16 iii. Butalbital, excluding drug products exempted by the federal17 drug enforcement administration (DEA);18 iv. Butobarbital (butethal);19 v. Talbutal;20 vi. Thiamylal;21 vii. Thiopental;22 viii. Vinbarbital.23 (4) Chlorhexadol;24 (5) Embutramide;25 (6) Any drug product containing gamma hydroxybutyric acid (GHB), in-26 cluding its salts, isomers, and salts of isomers, for which an applica-27 tion is approved under section 505 of the federal food, drug, and cos-28 metic act;29 (7) Ketamine, its salts, isomers, and salts of isomers-30 7285. (Some other names for ketamine: (+/-)-2-(2-chlorophenyl)-2-31 (methylamino)-cyclohexanone).32 (8) Lysergic acid;33 (9) Lysergic acid amide (LSA, LAA);34 (10) Methyprylon;35 (11) Perampanel, and its salts, isomers and salts of isomers;36 (12) Sulfondiethylmethane;37 (13) Sulfonethylmethane;38 (14) Sulfonmethane;39 (15) Tiletamine and zolazepam or any salt thereof.40 (d) Nalorphine.41 (e) Narcotic drugs. Unless specifically excepted or unless listed in42 another schedule:43 (1) Any material, compound, mixture, or preparation containing limited44 quantities of any of the following narcotic drugs, or any salts thereof:45 (i) i. Not more than 1.8 grams of codeine, or any of its salts,46 per 100 milliliters or not more than 90 milligrams per dosage unit,47 with an equal or greater quantity of an isoquinoline alkaloid of48 opium;49

16 (ii) ii. Not more than 1.8 grams of codeine, or any of its salts,1 per 100 milliliters or not more than 90 milligrams per dosage unit,2 with one (1) or more active, nonnarcotic ingredients in recognized3 therapeutic amounts;4 (iii) iii. Not more than 1.8 grams of dihydrocodeine, or any of5 its salts, per 100 milliliters or not more than 90 milligrams per6 dosage unit, with one (1) or more active, nonnarcotic ingredients7 in recognized therapeutic amounts;8 (iv) iv. Not more than 300 milligrams of ethylmorphine, or any of9 its salts, per 100 milliliters or not more than 15 milligrams per10 dosage unit, with one (1) or more active, nonnarcotic ingredients11 in recognized therapeutic amounts;12 (v) v. Not more than 500 milligrams of opium per 100 milliliters13 or per 100 grams, or not more than 25 milligrams per dosage unit,14 with one (1) or more active, nonnarcotic ingredients in recognized15 therapeutic amounts;16 (vi) vi. Not more than 50 milligrams of morphine, or any of its17 salts, per 100 milliliters or per 100 grams with one (1) or more ac-18 tive, nonnarcotic ingredients in recognized therapeutic amounts.19 (2) Any material, compound, mixture, or preparation containing any of20 the following narcotic drugs or their salts, as set forth below:21 (i) i. Buprenorphine.22 (ii) ii. [Reserved].23 (f) Anabolic steroids and human growth hormones. Any drug or hormonal24 substance, chemically and pharmacologically related to testosterone (other25 than estrogens, progestins and corticosteroids) that promotes muscle growth26 including any salt, ester or isomer of a drug or substance listed in this sub-27 section, if that salt, ester or isomer promotes muscle growth.28 (1) 13beta-ethyl-17beta-hydroxygon-4-en-3-one;29 (2) 17alpha-methyl-3alpha, 17beta-dihydroxy-5alpha-androstane;30 (3) 17alpha-methyl-3beta, 17beta-dihydroxy-5alpha-androstane;31 (4) 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-ene;32 (5) 17alpha-methyl-4-hydroxynandrolone;33 (6) 17alpha-methyl-5alpha-androstan-17beta-ol;34 (7) 17alpha-methyl-androst-2-ene-3,17beta-diol;35 (8) 17alpha-methyl-androsta-1,4-diene-3,17beta-diol;36 (9) 17alpha-methyl-androstan-3-hydroxyimine-17beta-ol;37 (10) 17alpha-methyl-delta1-dihydrotestosterone;38 (11) 17beta-hydroxy-androstano[2,3 3,2-c]isoxazole;39 (12) 17beta-hydroxy-androstano[2,3-d]isoxazole;40 (13) 18alpha-homo-3-hydroxy-estra-2,5(10)-dien-17-one;41 (14) 19-nor-4-androstenediol;42 (15) 19-nor-4-androstenedione;43 (16) 19-nor-4,9(10)-androstadienedione;44 (17) 19-nor-5-androstenediol;45 (18) 19-nor-5-androstenedione;46 (19) 1-androstenediol;47 (20) 1-androstenedione;48 (21) 2alpha,17alpha-dimethyl-17beta-hydroxy-5beta-androstan-3-one;49

17 (22) 2alpha,3alpha-epithio-17alpha-methyl-5alpha-androstan-17beta-1 ol;2 (23) [3,2-c]furazan-5alpha-androstan-17beta-ol;3 (24) [3,2-c]pyrazole-androst-4-en-17beta-ol;4 (25) 3alpha,17beta-dihydroxy-5alpha-androstane;5 (26) 3beta,17beta-dihydroxy-5alpha-androstane;6 (27) 3beta-hydroxy-estra-4,9,11-trien-17-one;7 (28) 4-androstenediol;8 (29) 4-androstenedione;9 (30) 4-chloro-17alpha-methyl-androsta-1,4-diene-3,17beta-diol;10 (31) 4-chloro-17alpha-methyl-androst-4-ene-3beta,17beta-diol;11 (32) 4-chloro-17alpha-methyl-17beta-hydroxy-androst-4-en-3-one;12 (33) 4-chloro-17alpha-methyl-17beta-hydroxy-androst-4-ene-3,11-13 dione;14 (34) 4-hydroxy-19-nortestosterone;15 (35) 4-hydroxy-androst-4-ene-3,17-dione;16 (36) 4-hydroxytestosterone;17 (37) 5alpha-androstan-3,17-dione;18 (38) 5alpha-androstan-3,6,17-trione;19 (39) 5-androstenediol;20 (40) 5-androstenedione;21 (41) 6alpha-methyl-androst-4-ene-3,17-dione;22 (42) 6-bromo-androsta-1,4-diene-3,17-dione;23 (43) 6-bromo-androstan-3,17-dione;24 (44) Androstenedione;25 (45) Bolasterone;26 (46) Boldenone;27 (47) Boldione;28 (48) Calusterone;29 (49) Chlorotestosterone (4-chlorotestosterone);30 (50) Clostebol;31 (51) Dehydrochlormethyltestosterone;32 (52) Delta1-dihydrotestosterone (1-testosterone);33 (53) Desoxymethyltestosterone (madol);34 (54) Dihydrotestosterone (4-dihydrotestosterone);35 (55) Drostanolone;36 (56) Estra-4,9,11-triene-3,17-dione;37 (57) Ethylestrenol;38 (58) Fluoxymesterone;39 (59) Formebulone Formebolone;40 (60) Furazabol;41 (61) Human growth hormones;42 (62) Mestanolone;43 (63) Mesterolone;44 (64) Methandienone;45 (65) Methandranone;46 (66) Methandriol;47 (67) Methandrostenolone;48 (68) Methasterone (2a, 17a-dimethyl-5a-androstan-17β-ol-3-one);49 (69) Methenolone;50

18 (70) Methyldienolone;1 (71) Methyltestosterone;2 (72) Methyltrienolone;3 (73) Mibolerone;4 (74) Nandrolone;5 (75) Norbolethone;6 (76) Norclostebol;7 (77) Norethandrolone;8 (78) Normethandrolone;9 (79) Oxandrolone;10 (80) Oxymesterone;11 (81) Oxymetholone;12 (82) Prostanozol (17β-hydroxy-5a-androstano[3,2-c]pyrazole);13 (83) Stanolone;14 (84) Stanozolol;15 (85) Stenbolone;16 (86) Testolactone;17 (87) Testosterone;18 (88) Testosterone cypionate;19 (89) Testosterone enanthate;20 (90) Testosterone propionate;21 (91) Tetrahydrogestrinone;22 (92) Trenbolone.23 Anabolic steroids that are expressly intended for administration24 through implants or injection to cattle or other nonhuman species, and that25 are approved by the federal Food and Drug Administration for such use, shall26 not be classified as controlled substances under this act and shall not be27 governed by its provisions.28 In addition to the penalties prescribed in article IV of the uniform29 controlled substances act, any person shall be guilty of a felony who pre-30 scribes, dispenses, supplies, sells, delivers, manufactures or possesses31 with the intent to prescribe, dispense, supply, sell, deliver or manufac-32 ture anabolic steroids or any other human growth hormone for purposes of33 enhancing performance in an exercise, sport or game or hormonal manipulation34 intended to increase muscle mass, strength or weight without a medical ne-35 cessity as determined by a physician.36 (g) Hallucinogenic substances.37 (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft38 gelatin capsule in the federal Food and Drug Administration ap-39 proved product -- 7369. (Some other names for dronabinol: (6aR-40 trans) -6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo41 [b,d]pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol).42 (h) The board may except by rule any compound, mixture, or preparation43 containing any stimulant or depressant substance listed in subsection (b)44 or (c) of this section from the application of all or any part of this act if45 the compound, mixture, or preparation contains one (1) or more active medic-46 inal ingredients not having a stimulant or depressant effect on the central47 nervous system, and if the admixtures are included therein in combinations,48 quantity, proportion, or concentration that vitiate the potential for abuse49

19 of the substances which have a stimulant or depressant effect on the central1 nervous system.2

SECTION 4. That Section 37-2711, Idaho Code, be, and the same is hereby3 amended to read as follows:4 37-2711. SCHEDULE IV. (a) Schedule IV shall consist of the drugs and5 other substances, by whatever official name, common or usual name, chemical6 name, or brand name designated, listed in this section.7 (b) Narcotic drugs. Unless specifically excepted or unless listed in8 another schedule, any material, compound, mixture, or preparation contain-9 ing any of the following narcotic drugs, or their salts calculated as the10 free anhydrous base or alkaloid, in limited quantities as set forth below:11 (1) No more than 1 milligram of difenoxin and not less than 25 micro-12 grams of atropine sulfate per dosage unit;13 (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-14 3-methyl-2-propionoxybutane);15 (3) 2- [(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol (in-16 cluding tramadol) Tramadol, including its salts, optical and geometric17 isomers, and salts of isomers.18 (c) Depressants. Unless specifically excepted or unless listed in an-19 other schedule, any material, compound, mixture, or preparation which con-20 tains any quantity of the following substances, including its salts, iso-21 mers, and salts of isomers whenever the existence of such salts, isomers, and22 salts of isomers is possible within the specific chemical designation:23 (1) Alfaxalone 5[alpha]-pregnan-3[alpha]-ol-11,20-dione;24 (2) Alprazolam;25 (3) Barbital;26 (4) Brexanolone (allopregnanolone);27 (4) (5) Bromazepam;28 (5) (6) Camazepam;29 (6) (7) Carisoprodol;30 (7) (8) Chloral betaine;31 (8) (9) Chloral hydrate;32 (9) (10) Chlordiazepoxide;33 (10) (11) Clobazam;34 (11) (12) Clonazepam;35 (12) (13) Clorazepate;36 (13) (14) Clotiazepam;37 (14) (15) Cloxazolam;38 (15) (16) Daridorexant;39 (16) (17) Delorazepam;40 (17) (18) Diazepam;41 (18) (19) Dichloralphenazone;42 (19) (20) Estazolam;43 (20) (21) Ethchlorvynol;44 (21) (22) Ethinamate;45 (22) (23) Ethyl loflazepate;46 (23) (24) Fludiazepam;47 (24) (25) Flurazepam;48 (25) (26) Fospropofol;49

20 (26) (27) Halazepam;1 (27) (28) Haloxazolam;2 (28) (29) Ketazolam;3 (29) (30) Lemborexant;4 (30) (31) Loprazolam;5 (31) (32) Lorazepam;6 (32) (33) Lormetazepam;7 (33) (34) Mebutamate;8 (34) (35) Medazepam;9 (35) (36) Meprobamate;10 (36) (37) Methohexital;11 (37) (38) Methylphenobarbital (mephobarbital);12 (38) (39) Midazolam;13 (39) (40) Nimetazepam;14 (40) (41) Nitrazepam;15 (41) (42) Nordiazepam;16 (42) (43) Oxazepam;17 (43) (44) Oxazolam;18 (44) (45) Paraldehyde;19 (45) (46) Petrichloral;20 (46) (47) Phenobarbital;21 (47) (48) Pinazepam;22 (48) (49) Prazepam;23 (49) (50) Quazepam;24 (50) (51) Remimazolam;25 (51) Serdexmethylpheniate;26 (52) Suvorexant;27 (53) Temazepam;28 (54) Tetrazepam;29 (55) Triazolam;30 (56) Zaleplon;31 (57) Zolpidem;32 (58) Zopiclone;33 (59) Zuranolone.34 (d) Fenfluramine -- Any material, compound, mixture, or preparation35 which contains any quantity of the following substances, including its36 salts, isomers (whether optical, position, or geometric), and salts of such37 isomers, whenever the existence of such salts, isomers, and salts of isomers38 is possible:39 (1) Dexfenfluramine;40 (2) Fenfluramine.41 (e) Stimulants. Unless specifically excepted or unless listed in an-42 other schedule, any material, compound, mixture, or preparation which con-43 tains any quantity of the following substances having a stimulant effect on44 the central nervous system, including its salts, isomers (whether optical,45 position, or geometric), and salts of such isomers whenever the existence46 of such salts, isomers, and salts of isomers is possible within the specific47 chemical designation:48 (1) Cathine ((+)-norpseudoephedrine);49 (2) Diethylpropion;50

21 (3) Fencamfamin;1 (4) Fenproporex;2 (5) Lorcaserin;3 (6) Mazindol;4 (7) Mefenorex;5 (8) Modafinil;6 (9) Pemoline (including organometallic complexes and chelates7 thereof);8 (10) Phentermine;9 (11) Pipradrol;10 (12) Serdexmethylpheniate;11 (12) (13) Sibutramine;12 (13) (14) SPA ((-)-1-dimethylamino-1,2-diphenylethane);13 (14) (15) Solriamfetol(2-amino-3-phenylpropyl carbamata; benzene-14 propanol, beta-amino-, carbamate(ester)).15 (f) Other substances. Unless specifically excepted, or unless listed16 in another schedule, any material, compound, mixture or preparation which17 contains any quantity of the following substances, including its salts:18 (1) Brexanolone (3A-hydroxy-5A-pregnan-20-one), allopregnanolone;19 (2) (1) Butorphanol (including its optical isomers);20 (3) (2) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-21 dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-22 yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical23 isomers) and its salts, isomers, and salts of isomers);24 (4) (3) Pentazocine.25 (g) The board may except, by rule, any compound, mixture, or prepara-26 tion containing any depressant substance listed in subsection (c) of this27 section from the application of all or any part of this act if the compound,28 mixture, or preparation contains one (1) or more active medicinal ingredi-29 ents not having a depressant effect on the central nervous system, and if the30 admixtures are included therein in combinations, quantity, proportion, or31 concentration that vitiate the potential for abuse of the substances which32 have a depressant effect on the central nervous system.33

SECTION 5. That Section 37-2713, Idaho Code, be, and the same is hereby34 amended to read as follows:35 37-2713. SCHEDULE V. (a) Schedule V shall consist of the drugs and36 other substances, by whatever official name, common or usual name, chemical37 name, or brand name designated, listed in this section.38 (b) Narcotic drugs. Unless specifically excepted or unless listed in39 another schedule, any material, compound, mixture, or preparation contain-40 ing any of the following narcotic drugs and their salts, as set forth below.41 (c) Narcotic drugs containing nonnarcotic active medicinal ingredi-42 ents. Any compound, mixture, or preparation containing any of the follow-43 ing limited quantities of narcotic drugs or salts thereof, which shall in-44 clude one (1) or more nonnarcotic active medicinal ingredients in sufficient45 proportion to confer upon the compound, mixture, or preparation, valuable46 medicinal qualities other than those possessed by the narcotic drug alone:47 (1) Not more than 200 milligrams of codeine per 100 milliliters or per48 100 grams;49

22 (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters1 or per 100 grams;2 (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters3 or per 100 grams;4 (4) Not more than 2.5 milligrams of diphenoxylate and not less than 255 micrograms of atropine sulfate per dosage unit;6 (5) Not more than 100 milligrams of opium per 100 milliliters or per 1007 grams;8 (6) Not more than 0.5 milligrams difenoxin and not less than 25 micro-9 grams of atropine sulfate per dosage unit.10 (d) Other substances. Unless specifically excepted or unless listed11 in another schedule, any material, compound, mixture or preparation which12 contains any quantity of the following substances, including its salts:13 (1) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]bu-14 tanamide) (also referred to as BRV; UCB-34714; Briviact) (including its15 salts);16 (2) Cenobamate[(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl]car-17 bamate;18 (3) Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic19 acid ethyl ester]-2779;20 (4) Ganaxolone (3-alpha-hydroxy-3-beta-methyl-5-alpha-preg-21 nan-20-one);22 (5) Lacosamide;23 (6) Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-car-24 bonyl)pyridine-2-yl)benzamide];25 (7) Pregabalin;26 (8) Pyrovalerone.27

SECTION 6. That Section 37-2716, Idaho Code, be, and the same is hereby28 amended to read as follows:29 37-2716. REGISTRATION REQUIREMENTS. (a) Every person who manufac-30 tures, distributes, prescribes, administers, or conducts research with any31 controlled substance within this state shall obtain annually biennially a32 registration issued by the board in accordance with Idaho law. All drug out-33 lets with a valid license or registration under chapter 17, title 54, Idaho34 Code, are exempt from obtaining a separate controlled substance registra-35 tion.36 (b) Every dispenser and prescriber, except veterinarians, shall also37 register with the division to obtain online access to the controlled sub-38 stances prescriptions database.39 (c) Persons registered by the board under this chapter may possess,40 manufacture, distribute, dispense, prescribe, administer, or conduct re-41 search with those substances to the extent authorized by their registration42 and licensing entity and in conformity with the other provisions of this43 chapter.44 (d) The following persons need not register and may lawfully possess45 controlled substances under this chapter:46 (1) An agent or employee of any person registered pursuant to this chap-47 ter, if he is acting in the usual course of his business or employment;48

23 (2) A common or contract carrier or warehouseman, or an employee1 thereof, whose possession of any controlled substance is in the usual2 course of business or employment;3 (3) An ultimate user or a person in possession of any controlled sub-4 stance pursuant to a lawful order of a practitioner or in lawful posses-5 sion of a schedule V substance.6 (e) A separate registration is required at each principal place of7 business or professional practice where the applicant manufactures, dis-8 tributes, administers, dispenses, or conducts research with controlled9 substances, except a separate registration is not required under this chap-10 ter for practitioners engaging in research with nonnarcotic controlled11 substances in schedules II through IV where the practitioner is already reg-12 istered under this chapter in another capacity.13 (f) Practitioners registered under federal law to conduct research14 with schedule I substances may conduct research with schedule I substances15 within this state upon registering in Idaho and furnishing the board with16 evidence of the practitioner's federal registration.17 (g) The board may inspect the establishment of a registrant or appli-18 cant for registration in accordance with Idaho law.19

SECTION 7. That Section 37-2717, Idaho Code, be, and the same is hereby20 amended to read as follows:21 37-2717. REGISTRATION. The board shall register an applicant to man-22 ufacture, prescribe, administer, dispense, distribute or conduct research23 with controlled substances included in sections 37-2705, 37-2707, 37-2709,24 37-2711 and 37-2713, Idaho Code, unless it determines that the issuance of25 that registration would be inconsistent with the public interest. In deter-26 mining the public interest, the board shall consider the following factors:27 (a) Maintenance of effective controls against diversion of controlled28 substances into other than legitimate medical, scientific, or industrial29 channels;30 (b) Compliance with applicable state and local law;31 (c) Any convictions of the applicant under any federal and state laws32 relating to any controlled substance;33 (d) Past experience Experience in the manufacture, dispensing,34 prescribing, administering, research or distribution of controlled sub-35 stances, and the existence in the applicant's establishment of effective36 controls against diversions;37 (e) Furnishing by the applicant of false or fraudulent material in any38 application filed under this chapter;39 (f) Restriction, suspension or revocation of the applicant's federal40 registration; and41 (g) Any other factors relevant to and consistent with the public health42 and safety.43

SECTION 8. That Section 37-2718, Idaho Code, be, and the same is hereby44 amended to read as follows:45

24 37-2718. DISCIPLINE. (a) A registration under section 37-2717, Idaho1 Code, may be restricted, suspended or revoked by the board upon a finding2 that the registrant:3 (1) Has furnished false or fraudulent material information in any ap-4 plication filed under this act;5 (2) Has been found guilty of a felony or misdemeanor under any state or6 federal law relating to any controlled substance;7 (3) Has had his federal registration restricted, suspended or revoked;8 or9 (4) Has violated this chapter, any rule of the board promulgated un-10 der this act, an order of the board or any federal regulation relating to11 controlled substances; provided, however, that no restriction, revoca-12 tion or suspension procedure be initiated under this paragraph without13 the board first giving notice of the procedure to the state licensing14 board with authority over the registrant's professional license.15 (b) The notice required in subsection (a)(4) of this section shall be16 given immediately in the event action is taken without an order to show cause17 as allowed under section 37-2719(b), Idaho Code. In all other cases, such18 notice shall be given as early as reasonably practicable without risking19 compromise of the board's investigation but no later than the earlier of:20 (1) Issuance of an order to show cause under section 37-2719(a), Idaho21 Code; or22 (2) Setting of a hearing for approval of a resolution of the matter23 through informal proceedings.24 (c) Restriction, revocation or suspension procedures arising solely25 from "practice-related issues" shall be referred by the board to such regis-26 trant's state licensing board.27 (1) Upon such referral, the registrant's state licensing board shall28 commence such investigation of the referred matter as it deems neces-29 sary and shall take action upon the registrant's license or shall inform30 the board of pharmacy, in writing, that it has investigated the referred31 matter and has concluded that no action is necessary.32 (2) For purposes of this section, the term "practice-related issues"33 refers to issues involving questions regarding the professional con-34 duct of the registrant within the scope of the registrant's profession.35 (d) The board may limit the revocation or suspension of a registration36 to the particular controlled substance with respect to which grounds for re-37 vocation or suspension exist.38 (e) If the board restricts, suspends or revokes a registration, all39 pertinent controlled substances owned or possessed by the registrant at the40 time of the restriction or suspension or the effective date of the revocation41 order may shall be placed under seal. No disposition may be made of sub-42 stances under seal until the time for taking an appeal has elapsed or until43 all appeals have been concluded unless a court, upon application therefor,44 orders the sale of perishable substances and the deposit of the proceeds45 of the sale with the court. Upon a revocation order becoming final, all46 controlled substances may shall be forfeited to the state for transfer to a47 reverse distributor.48 (f) The board shall promptly notify the bureau and the state licensing49 board with authority over the registrant's professional license of all or-50

25 ders restricting, suspending or revoking registration and all forfeitures1 of controlled substances.2 (g) In the event the drug enforcement administration or a state li-3 censing board with authority over a registrant's professional license or4 registration takes an action against the registrant in any fashion which5 suspends, restricts, limits or affects the registrant's ability to manufac-6 ture, distribute, prescribe, administer, dispense, or conduct research with7 any controlled substance, the professional licensing board shall promptly8 notify the board of pharmacy of the action.9 (1) Upon such action, the board of pharmacy shall be authorized to issue10 its order suspending, restricting, limiting or otherwise affecting the11 registrant's controlled substance registration in the same fashion as12 the professional licensing board action.13 (2) The board of pharmacy order may be issued without further hearing or14 proceeding, but shall be subject to the effect of any reversal or modi-15 fication of the professional licensing board action by reason of any ap-16 peal or rehearing.17

SECTION 9. That Section 37-2719, Idaho Code, be, and the same is hereby18 amended to read as follows:19 37-2719. ORDER TO SHOW CAUSE. (a) Except as set forth in section20 37-2718(g), Idaho Code, before denying, restricting, suspending or revok-21 ing a registration, or refusing a renewal of registration, the board shall22 serve upon the applicant or registrant an order to show cause, which shall23 require the applicant or registrant to show why the registration should not24 be restricted, denied, revoked, or suspended, or why the renewal should not25 be refused. The order to show cause shall contain a statement of the basis26 therefor for discipline and shall call upon the applicant or registrant to27 appear before the board at a time and place not less than thirty (30) days28 after the date of service of the order, but in the case of a an anticipated29 denial or of renewal of registration the show cause order shall be served not30 later than thirty (30) days before the expiration of the registration. These31 proceedings shall be conducted in accordance with chapter 52, title 67,32 Idaho Code, without regard to any criminal prosecution or other proceeding.33 Proceedings to refuse renewal of registration shall not abate the existing34 registration which shall remain in effect pending the outcome of the admin-35 istrative hearing.36 (b) The board may suspend, without an order to show cause, any regis-37 tration simultaneously with the institution of proceedings under section38 37-2718, Idaho Code, or where renewal of registration is refused, if it finds39 that there is an imminent danger to the public health or safety which war-40 rants this action. The suspension shall continue in effect until the conclu-41 sion of the proceedings, including judicial review thereof, unless sooner42 withdrawn by the board or dissolved by a court of competent jurisdiction.43 (c) In conjunction with a proceeding for denying, restricting, sus-44 pending or revoking a registration, or refusing a renewal of registration,45 and upon a finding of grounds for such denial, restriction, suspension,46 revocation or refusal to renew, the board may also impose an a reasonable47 administrative fine not to exceed two thousand dollars ($2,000) per occur-48 rence, which may include forfeiture of illicit profits, and the costs of49

26 prosecution and administrative costs of bringing the action including, but1 not limited to, attorney's fees and costs and costs of hearing transcripts.2

SECTION 10. That Section 37-2720, Idaho Code, be, and the same is hereby3 amended to read as follows:4 37-2720. RECORDS -- DRUG STORAGE -- INVENTORY. Persons registered un-5 der this chapter shall keep records, store controlled substances and main-6 tain inventories in conformance with the recordkeeping, storage and inven-7 tory requirements of state and federal law and with any additional rules the8 board issues.9

SECTION 11. That Section 37-2722, Idaho Code, be, and the same is hereby10 amended to read as follows:11 37-2722. ISSUING, DISTRIBUTING, AND DISPENSING OF CONTROLLED SUB-12 STANCES. No person shall issue or dispense a prescription drug order for a13 controlled substance unless it is in compliance with applicable state and14 federal law and rules of the board.15 (a) Controlled substances included in schedule I shall be distributed16 only by a registrant to another registrant pursuant to the federal drug en-17 forcement administration (DEA) order form 222.18 (b) Controlled substances included in schedule II shall:19 (1) Be distributed only by a registrant to another registrant pursuant20 to DEA order form 222.21 (2) Be dispensed only pursuant to a valid prescription drug order, ex-22 cept when dispensed directly by a prescriber.23 (3) Not be refilled.24 (4) Include a quantity that is both spelled out in English and written25 in numerical form, when a written prescription drug order is required.26 (c) Controlled substances included in schedule III or IV shall:27 (1) Be dispensed only pursuant to a valid prescription drug order, ex-28 cept when dispensed directly by a prescriber.29 (2) Not be filled or refilled more than six (6) months after the date30 thereof or be refilled more than five (5) times, unless renewed by the31 practitioner.32 (d) Controlled substances included in schedule V shall not be dis-33 tributed or dispensed other than for a medical purpose.34 (e) A pharmacist may dispense a controlled substance pursuant to a35 valid prescription drug order of an individual licensed in a jurisdiction36 other than the state of Idaho as long as the individual is acting within the37 jurisdiction, scope and authority of his license.38 (f) Prior to issuing to a patient a prescription for outpatient use39 for an opioid analgesic or benzodiazepine listed in schedule II, III, or40 IV, the prescriber or the prescriber's delegate shall review the patient's41 prescription drug history for the preceding twelve (12) months from the pre-42 scription drug monitoring program and evaluate the data for indicators of43 prescription drug diversion or misuse. This review is not required:44 (1) For patients:45 (i) i. Receiving treatment in an inpatient setting;46 (ii) ii. At the scene of an emergency or in an ambulance;47

27 (iii) iii. In hospice care; or1 (iv) iv. In a skilled nursing home care facility; or2 (2) For a prescription in a quantity intended to last no more than three3 (3) days.4 (g) Subsection (f) of this section shall be effective on and after Octo-5 ber 1, 2020, and shall apply only to individuals required by this chapter to6 register for the prescription drug monitoring program.7

SECTION 12. That Section 37-2726, Idaho Code, be, and the same is hereby8 amended to read as follows:9 37-2726. FILING PRESCRIPTIONS -- DATABASE. (1) All controlled sub-10 stances and opioid antagonists as defined in section 54-1704, Idaho Code,11 dispensed for humans shall be filed with the division electronically in a12 format established by the division. The division may require the filing of13 other prescriptions by law or rule. The division shall establish the in-14 formation to be submitted pursuant to the purposes of this section and the15 purposes set forth in section 37-2730A, Idaho Code.16 (2) The division shall create, operate and maintain a controlled17 substances prescriptions database containing the information submitted18 pursuant to subsection (1) of this section to be used for the purposes19 and subject to the terms, conditions and immunities described in section20 37-2730A, Idaho Code. The division shall retain the information submitted21 pursuant to subsection (1) of this section for a period of five (5) years from22 the date the controlled substance was dispensed. The database information23 must may be made available only to the following:24 (a) Authorized individuals employed by the division, Idaho's boards,25 or other states' licensing entities charged with the licensing and dis-26 cipline of practitioners;27 (b) Peace officers and investigators employed by federal, state and lo-28 cal law enforcement agencies engaged as a specified duty of their em-29 ployment in enforcing law regulating controlled substances;30 (c) Authorized individuals under the direction of the department of31 health and welfare for the purpose of monitoring and enforcing that32 department's responsibilities under the public health, medicare and33 medicaid laws;34 (d) A practitioner, licensed in Idaho or another state, having author-35 ity to prescribe controlled substances, or a delegate under the prac-36 titioner's supervision, to the extent the information relates specifi-37 cally to a current patient of the practitioner to whom the practitioner38 is prescribing or considering prescribing any controlled substance;39 (e) A pharmacist, licensed in Idaho or another state, having author-40 ity to dispense controlled substances, or a delegate under the pharma-41 cist's supervision, to the extent the information relates specifically42 to a current patient to whom that pharmacist is dispensing or consid-43 ering dispensing any controlled substance, or providing pharmaceutical44 care as defined in the Idaho pharmacy act;45 (f) An individual who is the recipient of a dispensed controlled sub-46 stance entered into the database may access records that pertain to that47 individual, upon the production of positive identification, or that in-48 dividual's designee upon production of a notarized release of informa-49

28 tion by that individual that is notarized or otherwise certified pur-1 suant to section 9-1406, Idaho Code;2 (g) Upon a lawful order issued by the presiding judge in a court of com-3 petent jurisdiction for the release of prescription monitoring program4 records of a named individual;5 (h) Prosecuting attorneys, deputy prosecuting attorneys, and special6 prosecutors of a county or city employed by federal, state, county, or7 local agencies and special assistant attorneys general from the office8 of the attorney general engaged in enforcing law regulating controlled9 substances; and10 (i) A medical examiner or coroner who is an officer of or employed by a11 state or local government, for determining a cause of death or for per-12 forming other duties authorized by law.13 (3) The division shall require pharmacists and prescribers, except14 veterinarians, to register with the division to obtain online access to the15 controlled substances prescriptions database.16 (4) (3) The division must maintain records on the information disclosed17 from the database, including:18 (a) The identification of each individual who requests or receives in-19 formation from the database and who that individual represents;20 (b) The information provided to each such individual; and21 (c) The date and time the information is requested or provided.22 (5) (4) The division shall ensure that only authorized individuals have23 access to the database.24 (6) (5)(a) Any person who knowingly misrepresents to the division that25 he is a person entitled under subsection (2) of this section to receive26 information from the controlled substances prescriptions database un-27 der the conditions therein provided, and who receives information from28 the controlled substances prescriptions database resulting from that29 misrepresentation, A person is guilty of a misdemeanor if such person:30 (i) Knowingly misrepresents to the division that he is a person31 entitled to receive information from the controlled substances32 prescriptions database pursuant to subsection (2) of this section33 and receives information from the controlled substances prescrip-34 tions database as a result of such misrepresentation;35 (ii) Knowingly discloses information obtained from the con-36 trolled substances prescriptions database that identifies an in-37 dividual patient to a person not authorized to receive or use such38 information under any state or federal law, rule, or regulation,39 without the lawful order of a court of competent jurisdiction, or40 without written authorization. The provisions of this subpara-41 graph shall not apply to disclosure of individual patient infor-42 mation by the patient himself or disclosure of individual patient43 information by a federal, state, or local prosecuting attorney,44 a deputy prosecuting attorney or special prosecutor, or a special45 assistant attorney general from the office of the attorney general46 in the course of a criminal proceeding, whether preconviction or47 post-conviction; or48 (iii) Intentionally shares or recklessly fails to safeguard a49 division-issued user account, login name, or password, result-50

29 ing in another person obtaining information from the controlled1 substances prescriptions database when such other person is not2 authorized to receive or use such information under the provisions3 of any state or federal law, rule, or regulation.4 (b) Any person who violates the provisions of paragraph (a) of this sub-5 section shall be guilty of a misdemeanor, punishable by imprisonment in6 a county jail not to exceed six (6) months, or by a fine not to exceed7 two thousand dollars ($2,000), or both. The foregoing criminal penalty8 is in addition to, and not in lieu of, any other civil or administrative9 penalty or sanction authorized by law.10 (7) Any person in possession, whether lawfully or unlawfully, of infor-11 mation from the controlled substances prescriptions database that identi-12 fies an individual patient and who knowingly discloses such information to a13 person not authorized to receive or use such information under any state or14 federal law or rule or regulation, or the lawful order of a court of competent15 jurisdiction, or without written authorization of the individual patient16 shall be guilty of a misdemeanor, punishable by imprisonment in a county jail17 not to exceed six (6) months, or by a fine not to exceed two thousand dollars18 ($2,000), or both. The foregoing criminal penalty is in addition to, and not19 in lieu of, any other civil or administrative penalty or sanction authorized20 by law. The provisions of this subsection shall not apply to disclosure of21 individual patient information by the patient himself. The provisions of22 this subsection shall not apply to disclosure of information by a prosecut-23 ing attorney, deputy prosecuting attorney or special prosecutor of a county24 or city or by a special assistant attorney general from the office of the at-25 torney general in the course of a criminal proceeding, whether preconviction26 or postconviction.27 (8) Any person with access to the division's online prescription mon-28 itoring program pursuant to a division-issued user account, login name and29 password who intentionally shares or recklessly fails to safeguard his user30 account, login name and password, resulting in another person not authorized31 to receive or use such information under the provisions of any state or fed-32 eral law, rule or regulation obtaining information from the controlled sub-33 stances prescriptions database, shall be guilty of a misdemeanor, punish-34 able by imprisonment in a county jail not to exceed six (6) months or by a fine35 not to exceed two thousand dollars ($2,000), or both. The foregoing criminal36 penalty is in addition to, and not in lieu of, any other civil or administra-37 tive penalty or sanction authorized by law.38 (9) (6) The division may, at its discretion, block access to certain39 controlled substances prescriptions database data if the division has rea-40 son to believe that access to the data is or may be used illegally.41 (10) (7) All costs associated with recording and submitting data as re-42 quired in this section are assumed by the dispensing practitioner recording43 and submitting the data.44 (11) (8) For purposes of this section, "delegate" means a nurse, medi-45 cal or office assistant, current student of a health profession if the health46 care staff, current health profession student of a licensed practitioner or47 registered graduate of such profession who may access the database, or a reg-48 istered pharmacy technician who is designated by a supervising practitioner49

30 or pharmacist to access the database according to the provisions of this sec-1 tion and who must register with the division for such access.2

SECTION 13. That Section 37-2731, Idaho Code, be, and the same is hereby3 amended to read as follows:4 37-2731. INFORMATION REQUIRED ON LABEL. A practitioner with statutory5 authority to dispense a controlled substance shall affix to the package a la-6 bel pursuant to board rule Idaho law.7

SECTION 14. An emergency existing therefor, which emergency is hereby8 declared to exist, this act shall be in full force and effect on and after9 July 1, 2026.10